P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
Am J Gastroenterol
; 116(Suppl 1): S8, 2021 Dec 01.
Article
in En
| MEDLINE
| ID: mdl-37461950
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Am J Gastroenterol
Year:
2021
Type:
Article
Affiliation country:
United States